Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer

Area of Science:

• Genomics
• Oncology
• Molecular Biology

Background:

• Breast cancer exhibits significant genomic complexity beyond simple driver mutations.
• Recurrent mutations like TP53 and PIK3CA are common, but numerous rare variants also contribute.
• New oncogenic events are emerging from noncoding genome regions and RNA editing.

Purpose of the Study:

• To review the current genomic landscape of breast cancer.
• To focus on genetic aberrations targeted by investigational drugs.
• To discuss the therapeutic implications of molecular abnormalities.

Main Methods:

• Advances in DNA and RNA sequencing technologies.
• Analysis of somatic and germline variants.
• Review of current literature on breast cancer genomics.

Main Results:

• Breast cancer genomes harbor dozens to hundreds of high-impact somatic and germline variants.
• The combined effect of genomic variations likely drives cancer behavior.
• Few robust molecular predictors for targeted therapy benefit exist, except for HER2 amplification.

Conclusions:

• The complexity of breast cancer genomics challenges treatment selection.
• Investigational targeted therapies should be administered within clinical trials or registry programs.
• Further research is needed to fully understand and leverage tumor target profiling for clinical utility.